Investment Management Corp of Ontario Decreases Position in Merck & Co., Inc. $MRK

Posted by Brenda Bartman on Jun 18th, 2026

Investment Management Corp of Ontario cut its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 4.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 290,226 shares of the company’s stock after selling 12,927 shares during the quarter. Investment Management Corp of Ontario’s holdings in Merck & Co., Inc. were worth $30,549,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MRK. Brighton Jones LLC raised its holdings in Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after acquiring an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in Merck & Co., Inc. by 52.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after acquiring an additional 3,941 shares during the last quarter. Diversify Advisory Services LLC raised its holdings in Merck & Co., Inc. by 94.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock valued at $2,590,000 after acquiring an additional 15,636 shares during the last quarter. Diversify Wealth Management LLC raised its holdings in Merck & Co., Inc. by 22.2% in the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock valued at $3,054,000 after acquiring an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Merck & Co., Inc. by 111.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after acquiring an additional 359,356 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Up 0.4%

Shares of NYSE MRK opened at $115.67 on Thursday. The company has a 50 day simple moving average of $116.22 and a 200-day simple moving average of $113.53. The company has a market capitalization of $285.69 billion, a P/E ratio of 32.58, a P/E/G ratio of 2.59 and a beta of 0.21. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. Merck & Co., Inc. has a 1 year low of $76.66 and a 1 year high of $125.14.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business’s revenue was up 4.9% compared to the same quarter last year. During the same quarter last year, the firm earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities research analysts predict that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.85 per share. The ex-dividend date is Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 95.77%.

Wall Street Analyst Weigh In

A number of analysts have commented on MRK shares. Citigroup started coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective for the company. Barclays started coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective for the company. Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a report on Monday, March 30th. Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. Finally, Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $128.18.

Read Our Latest Research Report on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.